IR@PKUHSC  > 北京大学第三临床医学院  > 药剂科
学科主题临床医学
Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies
Chen Xin; Yang Li; Zhai Suo-di
关键词Cardiovascular Risk Meta-analysis Pioglitazone Rosiglitazone Cohort Study
刊名CHINESE MEDICAL JOURNAL
2012-12-05
DOI10.3760/cma.j.issn.0366-6999.2012.23.025
125期:23页:4301-4306
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]RANDOMIZED CONTROLLED-TRIALS ; ACUTE MYOCARDIAL-INFARCTION ; HEART-FAILURE ; EVENTS ; THIAZOLIDINEDIONES ; MEDICATIONS ; MELLITUS ; DATABASE ; UPDATE ; DEATH
英文摘要

Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment for diabetic patients has not been thoroughly studied. We performed a meta-analysis to compare the risk of cardiovascular adverse effects in patients with type 2 diabetes treated with rosiglitazone compared to pioglitazone.

Methods The Cochrane Library, Pub Med, and Embase were searched to identify retrospective cohort studies assessing cardiovascular outcomes with rosiglitazone and pioglitazone. Meta-analysis of retrospective cohort studies was conducted using Rev Man 5.0 software to calculate risk ratios.

Results Of the 74 references identified, eight studies involving 945 286 patients fit the inclusion criteria for the analysis. The results of meta-analyses showed that, compared with pioglitazone, rosiglitazone therapy significantly increased the risk of myocardial infarction (risk ratios (RR) 1.17, 95% confidence interval (CI) 1.04-1.32; P=0.01), the risk of heart failure (RR 1.18, 95% CI 1.02-1.36; P=0.03), and total mortality (RR 1.13, 95% CI 1.08-1.20; P<0.000 01).

Conclusion Compared with pioglitazone, rosiglitazone was associated with an increased risk of myocardial infarction, heart failure, and all-cause mortality in diabetic patients. Chin Med J 2012;125(23):4301-4306

语种英语
WOS记录号WOS:000312748200025
引用统计
被引频次:27[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57352
专题北京大学第三临床医学院_药剂科
作者单位Peking Univ Third Hosp, Dept Pharm, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Chen Xin,Yang Li,Zhai Suo-di. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies[J]. CHINESE MEDICAL JOURNAL,2012,125(23):4301-4306.
APA Chen Xin,Yang Li,&Zhai Suo-di.(2012).Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.CHINESE MEDICAL JOURNAL,125(23),4301-4306.
MLA Chen Xin,et al."Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies".CHINESE MEDICAL JOURNAL 125.23(2012):4301-4306.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen Xin]的文章
[Yang Li]的文章
[Zhai Suo-di]的文章
百度学术
百度学术中相似的文章
[Chen Xin]的文章
[Yang Li]的文章
[Zhai Suo-di]的文章
必应学术
必应学术中相似的文章
[Chen Xin]的文章
[Yang Li]的文章
[Zhai Suo-di]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。